Ani Pharmaceuticals (ANIP) Gross Margin (2012 - 2026)
Ani Pharmaceuticals (ANIP) reported Gross Margin of 60.59% for Q1 2026, down 236.0% on a YoY basis from 44.55% in Q1 2025, and up 1.98% sequentially from 59.42% in Q4 2025.
Ani Pharmaceuticals (ANIP) Gross Margin (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals (ANIP) has 15 years of Gross Margin data on file, last reported at 60.59% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 236.0% year-over-year to 60.59%; the trailing twelve-month figure through Mar 2026 stood at 60.83% (up 149.0% YoY), and the FY2025 full-year result was 61.36%, up 209.0% from the prior year.
- Gross Margin grew to 60.59% in Q1 2026, from 59.42% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 64.7% in Q2 2025 to a low of 46.85% in Q1 2022.
- A 5-year average of 59.83% and a median of 60.59% in 2026 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin jumped 12529 bps in 2022 and plunged 604 bps in 2024, its largest moves.
- Tracing ANIP's Gross Margin over 5 years: stood at 61.45% in 2022, then dropped by 3 bps to 59.42% in 2023, then fell by 3 bps to 57.87% in 2024, then rose by 3 bps to 59.42% in 2025, then rose by 2 bps to 60.59% in 2026.
- Business Quant data shows ANIP's Gross Margin at 60.59% in Q1 2026, 59.42% in Q4 2025, and 59.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 60.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.59% |
| Dec 31, 2025 | 59.42% |
| Sep 30, 2025 | 59.01% |
| Jun 30, 2025 | 64.70% |
| Mar 31, 2025 | 62.95% |
| Dec 31, 2024 | 57.87% |
| Sep 30, 2024 | 57.48% |
| Jun 30, 2024 | 58.20% |
| Mar 31, 2024 | 64.23% |
| Dec 31, 2023 | 59.42% |
| Sep 30, 2023 | 63.51% |
| Jun 30, 2023 | 63.72% |
| Mar 31, 2023 | 64.69% |
| Dec 31, 2022 | 61.45% |
| Sep 30, 2022 | 60.76% |
| Jun 30, 2022 | 52.21% |
| Mar 31, 2022 | 46.85% |
| Dec 31, 2021 | 44.36% |
| Sep 30, 2021 | 53.11% |
| Jun 30, 2021 | 54.11% |